Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
long TASR here 9.58, stop LOD ... JTE
TASR, set up for a bullish engulfing today? We'll see ... JTE
Long TASR here 9.7 ... JTE
Added TASR here 9.47 ... JTE
Long CYTK 6.87 .. JTE
Nice jam going on with the TASR upgrade ... JTE
Added TASR long 8.74 ... JTE
Long TASR today here @ 8.88 ... JTE
Long GNTA 2.06 ... JTE
Long TASR 8.97 ... JTE
TASR, look for the shorts to lose the battle of 9 .. JTE
Added TASR here 8.56 ... JTE
TASR up 9%, should move higher ... JTE
Added TASR 7.98 ... JTE
Little AMRN up another 13% here, wants to run again ... JTE
Long TASR here 8.12 ... JTE
RMBS is known for historic squeezes, check the chart ... JTE
RMBS looks ready to rock ... JTE
Long RMBS 33.97 .... JTE
Long TASR 8.35 ... JTE
Long GNTA 1.86 ... JTE
Stick AMRN on your streamer here too ... JTE
The fireworks tonight will most likely be RMBS ... JTE
Long GNTA here @2.15, ton of shorts piled in earlier, can see a run to 2.50.
Long DNDN here 5.37 ... JTE
Adding AMRN here 2.56 ... JTE
TASR going green ... JTE
CYTK @ 6.99, another bio ready to pop ... JTE
GNTA having a nice morning ... JTE
Long TASR here 7.76 ... JTE
Amarin shares soar after Parkinson's animal study
Tue Jan 17, 2006 04:12 PM ET
LOS ANGELES, Jan 17 (Reuters) - Shares of British neuroscience drug developer Amarin Corp. Plc (AMRN.O: Quote, Profile, Research) rose nearly 52 percent on Tuesday as encouraging preclinical data extended a run-up that began in December with a private equity placement.
The stock gained $1.01 to close at $2.96 on Nasdaq, nearly triple the $1.01 per share purchase price of the $26.4 million private placement announced on Dec. 22, 2005.
"I think people are impressed with the quality of the financing," said Rodman & Renshaw analyst Elemer Piros.
He said the latest Amarin investors included a prominent venture capital firm and a value-oriented biotech investment fund.
Amarin is conducting pivotal Phase 3 trials of a drug called Miraxion as a treatment for Huntington's disease.
The company last week presented preclinical results indicating the molecule, a purified preparation of an omega-3 fatty acid, could be of therapeutic benefit in Parkinson's disease.
"It's still in animal studies, so anything can happen," Piros said.
Long TASR here 8.32 ... JTE
Little AMRN continues to climb today ... JTE
Long RMBS 33.95 ... JTE
TASR looks like it wants $10 soon ... JTE
RMBS filed another suit in CA. after hours Friday, hence another squeeze.
JTE
Long RMBS 31.77 ... time to watch the Cramerites scramble into the close.
JTE
Long GNTA 1.82, watching AMRN here ... JTE
Long TASR 8.27 ... JTE
Long TASR here @8.62 ... JTE